Please find below a full list of scientific papers and other publications that have referenced AdViSHE.
2020
Barbosa, C et al. “Economic Evaluation of Interventions to Address Opioid Misuse: A Systematic Review of Methods Used in Simulation Modeling Studies”. Value in Health; 2020, 23(8), pp. 1096 – 1108. DOI:https://doi.org/10.1016/j.jval.2020.03.015
Grimm, S.E., Pouwels, X., Ramaekers, B.L.T. et al. Development and Validation of the TRansparent Uncertainty ASsessmenT (TRUST) Tool for Assessing Uncertainties in Health Economic Decision Models. PharmacoEconomics 38, 205–216 (2020). https://doi.org/10.1007/s40273-019-00855-9
Grosso A, Neves de Faria RI, Bojke L, et al. “Cost-effectiveness of strategies preventing late-onset infection in preterm infants”. Archives of Disease in Childhood 2020;105:452-457. https://adc.bmj.com/content/105/5/452
Hassett, M.J., Li, H., Burstein, H.J. et al. Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat 181, 43–51 (2020). https://doi.org/10.1007/s10549-020-05587-5
Johansen, P., Howard, D., Bishop, R. et al. Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. PharmacoEconomics 38, 485–497 (2020). https://doi.org/10.1007/s40273-019-00881-7
Joshi, B., Moray, K.V., Sachin, O. et al. “Cost Effectiveness of Introducing Etonorgestrel Contraceptive Implant into India’s Current Family Welfare Programme”. Appl Health Econ Health Policy (2020). https://doi.org/10.1007/s40258-020-00605-5
Judge A, Carr A, Price A, Garriga C, Cooper C, Prieto-Alhambra D, et al. The impact of the enhanced recovery pathway and other factors on outcomes and costs following hip and knee replacement: routine data study. Health Serv Deliv Res 2020;8(4). https://doi.org/10.3310/hsdr08040
Loong, H.H., Wong, C.K.H., Leung, L.K.S. et al. Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong. PharmacoEconomics Open 4, 235–247 (2020). https://doi.org/10.1007/s41669-019-00178-7
Mandavia, Rishi; Horstink, Yvette M.; Grutters, Janneke P.C.; Landry, Evie; May, Carl; Rovers, Maroeska; Schilder, Anne G.M.; Scholte, Mirre. “The Potential Added Value of Novel Hearing Therapeutics: An Early Health Economic Model for Hearing Loss”. Otology & Neurotology: September 2020 – Volume 41 – Issue 8 – p 1033-1041. doi: 10.1097/MAO.0000000000002744
Petersohn S, Pouwels X, Ramaekers B, ten Cate-Hoek A, Joore M. Rivaroxaban plus aspirin for the prevention of ischaemic events in patients with cardiovascular disease: a cost-effectiveness study. European Journal of Preventive Cardiology. 2020;27(13):1354-1365. doi:10.1177/2047487320913380
Pouwels Xavier G. L. V. , Ramaekers Bram L. T. , Geurts Sandra M. E. et al. (2020) An economic evaluation of eribulin for advanced breast cancer treatment based on the Southeast Netherlands advanced breast cancer registry, Acta Oncologica, 59:9, 1123-1130, DOI: 10.1080/0284186X.2020.1775289
Pritchard MG, Murphy J, Cheng L, et al. Enhanced recovery following hip and knee arthroplasty: a systematic review of cost-effectiveness evidence. BMJ Open 2020;10:e032204. doi:10.1136/bmjopen-2019-032204
Retèl, Valesca P. et al. Cost-effectiveness analysis of the 70-gene signature compared with clinical assessment in breast cancer based on a randomised controlled trial. European Journal of Cancer, Volume 137, 193 – 203. DOI:https://doi.org/10.1016/j.ejca.2020.07.002
Schlueter M, Rouse P, Pitcher A, Graham-Clarke PL, Nicolay C & Fakhouri W (2020) A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis, Expert Review of Pharmacoeconomics & Outcomes Research, 20:2, 221-228, DOI: 10.1080/14737167.2020.1744435
Scholte, Mirre et al. Modelling Study with an Interactive Model Assessing the Cost-effectiveness of 68Ga Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography and Nano Magnetic Resonance Imaging for the Detection of Pelvic Lymph Node Metastases in Patients with Primary Prostate Cancer. European Urology Focus, Volume 6, Issue 5, 967 – 974. https://doi.org/10.1016/j.euf.2019.02.013
Scholte M, de Gouw DJ, Klarenbeek BR, et al. Selecting esophageal cancer patients for lymphadenectomy after neoadjuvant chemoradiotherapy: a modeling study. BMJ Surgery, Interventions, & Health Technologies 2020;2:e000027. doi: 10.1136/bmjsit-2019-000027
Sculpher, M., Palmer, S. After 20 Years of Using Economic Evaluation, Should NICE be Considered a Methods Innovator?. PharmacoEconomics 38, 247–257 (2020). https://doi.org/10.1007/s40273-019-00882-6
Simoes Correa-Galendi, J., del Pilar Estevez Diz, M., Stock, S. et al. Economic Modelling of Screen-and-Treat Strategies for Brazilian Women at Risk of Hereditary Breast and Ovarian Cancer. Appl Health Econ Health Policy (2020). https://doi.org/10.1007/s40258-020-00599-0
Smith H, Varshoei P, Boushey R, Kuziemsky C. Use of Simulation Modeling to Inform Decision Making for Health Care Systems and Policy in Colorectal Cancer Screening: Protocol for a Systematic Review. JMIR Res Protoc 2020;9(5):e16103. DOI: 10.2196/16103
Widén, J., Ivarsson, M., Schalin, L. et al. Cost-Effectiveness Analysis of Patiromer in Combination with Renin–Angiotensin–Aldosterone System Inhibitors for Chronic Kidney Disease in Sweden. PharmacoEconomics 38, 747–764 (2020). https://doi.org/10.1007/s40273-020-00902-w
(2020) Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis, Expert Review of Pharmacoeconomics & Outcomes Research, 20:3, 269-279, DOI: 10.1080/14737167.2019.1632194
Willis, M., Fridhammar, A., Gundgaard, J. et al. Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. PharmacoEconomics 38, 953–969 (2020). https://doi.org/10.1007/s40273-020-00922-6
2019
Briggs, A.D.M., Wolstenholme, J. & Scarborough, P. Estimating the cost-effectiveness of salt reformulation and increasing access to leisure centres in England, with PRIMEtime CE model validation using the AdViSHE tool. BMC Health Serv Res 19, 489 (2019). https://doi.org/10.1186/s12913-019-4292-x
Büyükkaramikli, N.C., Rutten-van Mölken, M.P.M.H., Severens, J.L. et al. TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility. PharmacoEconomics 37, 1391–1408 (2019). https://doi.org/10.1007/s40273-019-00844-y
Chongmelaxme, B., Phisalprapa, P., Sawangjit, R. et al. Weight Reduction and Pioglitazone are Cost-Effective for the Treatment of Non-Alcoholic Fatty Liver Disease in Thailand. PharmacoEconomics 37, 267–278 (2019). https://doi.org/10.1007/s40273-018-0736-0
Ehteshami-Afshar, Solmaz et al. A Systematic Review of Decision-Analytic Models for Evaluating Cost-Effectiveness of Asthma Interventions. Value in Health, Volume 22, Issue 9, 1070 – 1082. DOI:https://doi.org/10.1016/j.jval.2019.03.016
Frederix, G.W.J. Check Your Checklist: The Danger of Over- and Underestimating the Quality of Economic Evaluations. PharmacoEconomics Open (2019). https://doi.org/10.1007/s41669-019-0118-3
Ghabri, S., Stevenson, M., Möller, J. et al. Trusting the Results of Model-Based Economic Analyses: Is there a Pragmatic Validation Solution?. PharmacoEconomics 37, 1–6 (2019). https://doi.org/10.1007/s40273-018-0711-9
Gout-Zwart, J.J., Olde Hengel, E.H.J., Hoogland, P. et al. Budget Impact Analysis of a Renal Point-of-Care Test in Dutch Community Pharmacies to Prevent Antibiotic-Related Hospitalizations. Appl Health Econ Health Policy 17, 55–63 (2019). https://doi.org/10.1007/s40258-018-0426-2
Gumbie, M., Parkinson, B., Cutler, H. et al. Is Reclassification of the Oral Contraceptive Pill from Prescription to Pharmacist-Only Cost Effective? Application of an Economic Evaluation Approach to Regulatory Decisions. PharmacoEconomics 37, 1049–1064 (2019). https://doi.org/10.1007/s40273-019-00804-6
Gupta V, Willis M, Johansen P et al. Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. Value in Health Regional Issues 18, 65-73 (2019). https://doi.org/10.1016/j.vhri.2018.06.002.
Hampson, G., Roberts, S.L.E., Lucas, A. et al. An economic analysis of human milk supplementation for very low birth weight babies in the USA. BMC Pediatr 19, 337 (2019). https://doi.org/10.1186/s12887-019-1691-4
Hung A, Slejko JF, Lugo A et al. Validating a Budget Impact Model Using Payer Insight and Claims Data: A Framework and Case Study. Journal of Managed Care & Specialty Pharmacy 2019 25:8, 913-921. https://doi.org/10.18553/jmcp.2019.25.8.913
Incerti, D., Curtis, J.R., Shafrin, J. et al. A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. PharmacoEconomics 37, 829–843 (2019). https://doi.org/10.1007/s40273-018-00765-2
Jiang, Y., Ni, W. Economic Evaluation of the 2016 Chinese Guideline and Alternative Risk Thresholds of Initiating Statin Therapy for the Management of Atherosclerotic Cardiovascular Disease. PharmacoEconomics 37, 943–952 (2019). https://doi.org/10.1007/s40273-019-00791-8
Job F.M. van Boven, Susanne J. van de Hei, Mohsen Sadatsafavi. Making sense of cost-effectiveness analyses in respiratory medicine: a practical guide for non-health economists. European Respiratory Journal Mar 2019, 53 (3) 1801816; DOI: 10.1183/13993003.01816-2018
Kent, S., Becker, F., Feenstra, T. et al. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. PharmacoEconomics 37, 1305–1312 (2019). https://doi.org/10.1007/s40273-019-00825-1
Kazemian P, Wexler DJ, Fields NF et al. Diabetes Technology & Therapeutics. Jun 2019.344-355. http://doi.org/10.1089/dia.2018.0393
Leal, J, Morrow, LM, Khurshid, W, Pagano, E, Feenstra, T. Decision models of prediabetes populations: A systematic review. Diabetes Obes Metab. 2019; 21: 1558– 1569. https://doi.org/10.1111/dom.13684
Moriarty F, Cahir C, Bennett K, et al. Economic impact of potentially inappropriate prescribing and related adverse events in older people: a cost-utility analysis using Markov models. BMJ Open 2019;9:e021832. doi: 10.1136/bmjopen-2018-021832
Sampson, C.J., Arnold, R., Bryan, S. et al. Transparency in Decision Modelling: What, Why, Who and How?. PharmacoEconomics 37, 1355–1369 (2019). https://doi.org/10.1007/s40273-019-00819-z
Scholte, M, Hentschel, MA, Hannink, G, et al. In search of the most cost‐effective monitoring strategy for vestibular schwannoma: A decision analytical modelling study. Clin Otolaryngol. 2019; 44: 525– 533. https://doi.org/10.1111/coa.13326
Stein, E., Xie, J., Duchesneau, E. et al. Cost Effectiveness of Midostaurin in the Treatment of Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in the United States. PharmacoEconomics 37, 239–253 (2019). https://doi.org/10.1007/s40273-018-0732-4
Verhoef LM, Bos DPG, van den Ende CHM et al. (2019) Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study, Scandinavian Journal of Rheumatology, 48:6, 439-447, DOI: 10.1080/03009742.2019.1613674
Zakiyah, N., van Asselt, A.D.I., Setiawan, D. et al. Cost-Effectiveness of Scaling Up Modern Family Planning Interventions in Low- and Middle-Income Countries: An Economic Modeling Analysis in Indonesia and Uganda. Appl Health Econ Health Policy 17, 65–76 (2019). https://doi.org/10.1007/s40258-018-0430-6
2018
Alaujan, Shiekha (2018) A programme of feasibility studies to develop a randomised controlled trial to assess pain management services for people with fibromyalgia or chronic widespread pain. PhD thesis, University of Nottingham. http://eprints.nottingham.ac.uk/52085/
Beca, J., Husereau, D., Chan, K.K.W. et al. Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment. PharmacoEconomics 36, 7–15 (2018). https://doi.org/10.1007/s40273-017-0583-4
Carlson, J.J., Suh, K., Orfanos, P. et al. Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer. PharmacoEconomics 36, 495–504 (2018). https://doi.org/10.1007/s40273-018-0625-6
Crown, W et al. Application of Constrained Optimization Methods in Health Services Research: Report 2 of the ISPOR Optimization Methods Emerging Good Practices Task Force. Value in Health, Volume 21, Issue 9, 1019 – 1028. DOI:https://doi.org/10.1016/j.jval.2018.05.003
Degeling K, Franken MD, May AM et al. Matching the model with the evidence: comparing discrete event simulation and state-transition modeling for time-to-event predictions in a cost-effectiveness analysis of treatment in metastatic colorectal cancer patients. Cancer Epidemiology 57, 60-67 (2018). https://doi.org/10.1016/j.canep.2018.09.008
Ebrahem AS and Oremus M (2018) A pharmacoeconomic evaluation of cholinesterase inhibitors and memantine for the treatment of Alzheimer’s disease, Expert Opinion on Pharmacotherapy, 19:11, 1245-1259, DOI: 10.1080/14656566.2018.1499727
Fong Soe Khioe, R., Skedgel, C., Hart, A. et al. Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. PharmacoEconomics 36, 349–358 (2018). https://doi.org/10.1007/s40273-017-0594-1
Ghabri, S., Cleemput, I. & Josselin, J. Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines. PharmacoEconomics 36, 127–130 (2018). https://doi.org/10.1007/s40273-017-0603-4
Gharaibeh, M., McBride, A., Alberts, D.S. et al. Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. PharmacoEconomics 36, 1273–1284 (2018). https://doi.org/10.1007/s40273-018-0678-6
Gharaibeh, M., McBride, A., Alberts, D.S. et al. Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. PharmacoEconomics 36, 1333–1343 (2018). https://doi.org/10.1007/s40273-018-0684-8
Hermansson, J., Kahan, T. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe. PharmacoEconomics 36, 205–213 (2018). https://doi.org/10.1007/s40273-017-0578-1
Hernandez, L., O’Donnell, M. & Postma, M. Modeling Approaches in Cost-Effectiveness Analysis of Disease-Modifying Therapies for Relapsing–Remitting Multiple Sclerosis: An Updated Systematic Review and Recommendations for Future Economic Evaluations. PharmacoEconomics 36, 1223–1252 (2018). https://doi.org/10.1007/s40273-018-0683-9
Kim, Y., Song, J.Y., Jang, H. et al. Cost Effectiveness of Quadrivalent Influenza Vaccines Compared with Trivalent Influenza Vaccines in Young Children and Older Adults in Korea. PharmacoEconomics 36, 1475–1490 (2018). https://doi.org/10.1007/s40273-018-0715-5
Koffijberg H, Rothery C, Chalkidou K, Grutters J. Value of Information Choices that Influence Estimates: A Systematic Review of Prevailing Considerations. Medical Decision Making. 2018;38(7):888-900. doi:10.1177/0272989X18797948
McDonald, S.A., Azzeri, A., Shabaruddin, F.H. et al. Projections of the Healthcare Costs and Disease Burden due to Hepatitis C Infection under Different Treatment Policies in Malaysia, 2018–2040. Appl Health Econ Health Policy 16, 847–857 (2018). https://doi.org/10.1007/s40258-018-0425-3
McManus, E., Sach, T. & Levell, N. The Use of Decision–Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal. PharmacoEconomics 36, 51–66 (2018). https://doi.org/10.1007/s40273-017-0564-7
Murphy J, Pritchard MG, Cheng LY, et al. Cost-effectiveness of enhanced recovery in hip and knee replacement: a systematic review protocol. BMJ Open 2018;8:e019740. doi: 10.1136/bmjopen-2017-019740
Padmasawitri TIA, Frederix GW, Alisjahbana B, Klungel O, Hövels AM (2018) Disparities in model-based cost-effectiveness analyses of tuberculosis diagnosis: A systematic review. PLOS ONE 13(5): e0193293. https://doi.org/10.1371/journal.pone.0193293
Peters, M.L., de Meijer, C., Wyndaele, D. et al. Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer. Appl Health Econ Health Policy 16, 133–143 (2018). https://doi.org/10.1007/s40258-017-0350-x
Roberts, S., Craig, D., Adler, A. et al. Economic evaluation of type 2 diabetes prevention programmes: Markov model of low- and high-intensity lifestyle programmes and metformin in participants with different categories of intermediate hyperglycaemia. BMC Med 16, 16 (2018). https://doi.org/10.1186/s12916-017-0984-4
Rolden, H., Van der Wilt, G., Maas, A., & Grutters, J. (2018). The gap between economic evaluations and clinical practice: A systematic review of economic evaluations on dabigatran for atrial fibrillation. International Journal of Technology Assessment in Health Care, 34(3), 327-336. doi:10.1017/S0266462318000211
Stollenwerk, B., Iannazzo, S., Akehurst, R. et al. A Decision-Analytic Model to Assess the Cost-Effectiveness of Etelcalcetide vs. Cinacalcet. PharmacoEconomics 36, 603–612 (2018). https://doi.org/10.1007/s40273-017-0605-2
2017
Beca, J, Husereau, D, Chan, KKW, Hawkins, N, Hoch, JS. “Oncology Modeling for Fun and Profit! Key Steps for Busy Analysts in Health Technology Assessment” PharmEcon;2017. DOI: 10.1007/s40273-017-0583-4
Boer, PT de, Maanen, BM van, Damm, O, Ultsch, B, Dolk, FCK, Crépey, P, Pitman, R, Wilschut JC, Postma, MJ. “A systematic review of the health economic consequences of quadrivalent influenza vaccination” Exp Rev Pharmecon & Outc Res; 2017:17(3), p249 DOI: 10.1080/14737167.2017.1343145
Corro Ramos, I, Voorn, GAK van, Vemer, P, Feenstra, TL, Al, MJ. “A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data” Value Health; 2017:20(8), p1041. DOI: 10.1016/j.jval.2017.04.016
Dasbach, EJ, Elbasha, EH. “Verification of Decision-Analytic Models for Health Economic Evaluations: An Overview” PharmEcon:2017;35(7), p673 DOI: 10.1007/s40273-017-0508-2
Degeling, K, IJzerman, MJ, Koopman, M, Koffijberg, H. “Accounting for parameter uncertainty in the definition of parametric distributions used to describe individual patient variation in health economic models” BMC Med Res Meth:2017;17(1) DOI: 10.1186/s12874-017-0437-y
Degeling, K, Schivo, S, Mehra, N, Koffijberg, H, Langerak, R, Bono JS de, IJzerman, MJ. “Comparison of Timed Automata with Discrete Event Simulation for Modeling of Biomarker-Based Treatment Decisions: An Illustration for Metastatic Castration-Resistant Prostate Cancer” Value Health: 2017; 20(10), p1411 DOI: 10.1016/j.jval.2017.05.024
Deshmukh, AA, Shirvani, SM, Lal, L, Swint, JM, Cantor, SB, Smith, BD, Likhacheva, A. “Cost-effectiveness Analysis Comparing Conventional, Hypofractionated, and Intraoperative Radiotherapy for Early-Stage Breast Cancer” JNCI;2017:109(11) DOI: 10.1093/jnci/djx068
Elliott, RA, Tanajewski, L, Gkountouras, G, Avery, AJ, Barber, N, Mehta, R, Boyd, MJ, Latif, A, Chuter, A, Waring, J. “Cost Effectiveness of Support for People Starting a New Medication for a Long-Term Condition Through Community Pharmacies: An Economic Evaluation of the New Medicine Service (NMS) Compared with Normal Practice” PharmEcon;2017:35(12), p1237. DOI: 10.1007/s40273-017-0554-9
Frederix, G, Vemer, P. “Decision analytic modelling: The need for disease specific model standardization” Link Chapter in Tordrup, D, Stephan, L, Attwill, A, Karunaratna, S, Bertollini R. “Research Agenda for Health Economic Evaluation” Health Economic Evidence Review, World Health Organization, December 2014
Hermansson, J, Kahan, T. Systematic Review of Validity Assessments of Framingham Risk Score Results in Health Economic Modelling of Lipid-Modifying Therapies in Europe” PharmEcon;2017. DOI: 10.1007/s40273-017-0578-1
Hoorn, R van, Tummers, M, Kievit, W, Wilt GJ van der. (eds.) “Guidance for the assessment of treatment moderation and patients’ preferences” 2016 Project report for Integrated Health Technology Assessment for Evaluating Complex Technologies (INTEGRATE-HTA) Link
Huang, M, Lou, Y, Pellissier, J, Burke, T, Liu, FX, Xu R, Velcheti, V. “Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States” PharmEcon: 2017;35(8), p831 DOI: 10.1007/s40273-017-0527-z
Karnon, J, Afzali, HHA, Putro, GVAA, Thant, PW, Dompok, A, Cox, I, Chikhwaza, OH, Wang, X, Mwangangi, MM, Farransahat, M, Cameron, I. “A Cost-Effectiveness Model for Frail Older Persons: Development and Application to a Physiotherapy-Based Intervention” Appl Health Econ Health Pol, 2017:15(5), P635 DOI: 10.1007/s40258-017-0324-z
Khioe, RFS, Skedgel, C, Hart, A, Lewis MPN, Alexandre, L. “Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis” PharmEcon:2017 DOI: 10.1007/s40273-017-0594-1
Koleva-Kolarova, RG, Zhan, Z, Greuter, MJW, Feenstra, TL, Bock, GH de. “Correspondence ? Reply to THEBREAST-D-15-702” Breast:2016;27, p184 DOI: 10.1016/j.breast.2016.03.001
Landfeldt, E, Alfredsson, L, Straub, V, Lochmüller, H, Bushby, K, Lindgren, P. “Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis” PharmEcon:2017;35(2), p249 DOI: 10.1007/s40273-016-0461-5
Langley PC. Denkbeeldige Wereld: The New Dutch Guidelines for Economic Evaluations in Healthcare. Innovations in Pharmacy 2017;8(1). DOI: https://doi.org/10.24926/21550417.1344
Langley PC. Validating Imaginary Worlds? The AdViSHE Assessment Tool. Innovations in Pharmacy 2017;8(1). DOI: https://doi.org/10.24926/21550417.1343
Leal J, Khurshid W, Pagano E, et al. Computer simulation models of pre-diabetes populations: a systematic review protocol. BMJ Open 2017;7:e014954. doi: 10.1136/bmjopen-2016-014954
McManus, E, Sach, T, Levell, N. “The Use of Decision-Analytic Models in Atopic Eczema: A Systematic Review and Critical Appraisal” PharmEcon;2017. DOI: 10.1007/s40273-017-0564-7
Pelligra, CG, Parikh, K, Guo, S, Chandler, C, Mouro, J, Abouzaid, S, Ailawadhi, S. “Cost-effectiveness of Pomalidomide, Carfilzomib, and Daratumumab for the Treatment of Patients with Heavily Pretreated Relapsed?refractory Multiple Myeloma in the United States” Clin Ther: 2017;39(10), p1986 DOI: 10.1016/j.clinthera.2017.08.010
Peters, ML, Meijer, C de, Wyndaele, D, Noordzij, W, Leliveld-Kors, AM, Bosch, J van den, Berg, PH van den, Baka, A, Gaultney, JG. “Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer” Appl Health Econ Health Pol, 2017 DOI: 10.1007/s40258-017-0350-x
Pol, S van der, Degener, F, Postma MJ, Vemer P. “An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands” Value Health:2017:20(3), p388 DOI: 10.1016/j.jval.2016.10.015
Quante AM. Risk-Stratified Breast Cancer Screening and Non-Adherence in Germany. Value in Health; 2017:20:9. A442. https://doi.org/10.1016/j.jval.2017.08.251
Schans, S van der, Goossens, LMA, Boland, MRS, Kocks, JWH, Postma, MJ, Boven, JFM van, Rutten-van Mölken, MPMH. “Systematic Review and Quality Appraisal of Cost-Effectiveness Analyses of Pharmacologic Maintenance Treatment for Chronic Obstructive Pulmonary Disease: Methodological Considerations and Recommendations” PharmEcon;2017:35(1), p43. DOI: 10.1007/s40273-016-0448-2
Schiller-Frühwirth, IC, Jahn, B, Arvandi M, Siebert, U. “Cost-Effectiveness Models in Breast Cancer Screening in the General Population: A Systematic Review” Appl Health Econ Health Pol, 2017:15(3), p333 DOI: 10.1007/s40258-017-0312-3
Willis, M, Johansen, P, Nilsson, A, Asseburg, C. “Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)” PharmEcon;2017:35,(3), p375. DOI: 10.1007/s40273-016-0471-3
2016
Adarkwah, CC, Gils, PF van, Hiligsmann, M, Evers, SMAA. “Risk of bias in model-based economic evaluations: the ECOBIAS checklist” Exp Rev Pharmacoecon & Outc Res;2016:16(14), P513-523 T and F Online Researchgate
Boer, PT de, Frederix, GWJ, Feenstra TL, Vemer P. “Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer” PharmEcon;2016:34(9), p833 DOI: 10.1007/s40273-016-0410-3
Karnon, J. Model Validation: Has it’s Time Come?. PharmacoEconomics 34, 829–831 (2016). https://doi.org/10.1007/s40273-016-0415-y
Koleva-Kolarova, R et al. The Breast, Volume 27, 184 – 18. DOI:https://doi.org/10.1016/j.breast.2016.03.001
Wijnen, BFM, Mastrigt, GAPG Van, Redekop, WK, Majoie, HJM, Kinderen, RJA de, Evers, SMAA. “How to prepare a systematic review of economic evaluations for informing evidence-based healthcare decisions: data extraction, risk of bias, and transferability (part 3/3)” Exp Rev Pharmecon & Outc Res: 2016; 16(6), p723
DOI: 10.1080/14737167.2016.1246961
advishe.wordpress.com 